In early-stage HR+, HER2-, N0 breast cancer, who may benefit from chemotherapy?
Know with confidence which patients may benefit from chemotherapy and which patients may not1-4
TAILORx results eliminate uncertainty around intermediate results and show that most patients may not benefit from chemotherapy1,2
Adjuvant chemotherapy may be guided with Oncotype DX test to identify2,4:
- the majority of patients with no chemotherapy benefit
- the important minority for whom chemotherapy may be life-saving
TAILORx shows that clinical risk features alone are not sufficient to determine chemotherapy benefit1,2
73%
of patients in TAILORx with high clinical risk* had Recurrence Score results 0-25 and may have been overtreated without the Recurrence Score result**2
43%
of patients in TAILORx with Recurrence Score results 26-100 had low clinical risk* and may have been undertreated without the Recurrence Score result**2
**Assuming that adjuvant chemotherapy would have been prescribed or not based on clinical risk
The largest randomised adjuvant breast cancer treatment trial ever conducted
TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.
TAILORX: TRANSFORMING THE TREATMENT OF BREAST CANCER
Learn more about the TAILORx trial in the video below
Largest ever adjuvant breast cancer treatment clinical trial results - 5-year outcomes, 9-year outcomes and 12-year results5:
-
REFERENCES